- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
New Drug Combination Promises SVR 6 in hepatitis C
Achillon's NS5A inhibitor is being evaluated with Gilead's Sovaldi in treatment-naive hepatitis C patients.
Achillion Pharmaceuticals Inc's experimental hepatitis C drug, when used with Gilead Sciences Inc's Sovaldi, eradicated signs of the virus in 6 weeks, the shortest duration and highest response achieved by any 2-drug treatment
Achillion's shares rose as much as 19 percent to $12.85 on Monday on investor's hopes that an all-Achillion combination could be as effective as Gilead's and AbbVie Inc's current therapies.
The estimated $20 billion market for hepatitis C drugs has developed at a lightning pace in recent years, with several companies including Gilead, AbbVie and Merck & Co Inc working on faster, more potent ways to cure the liver-destroying virus, which affects more than 170 million globally.
Link to the news on Reuters: http://reut.rs/1vehaXY
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen
